Joining LabCorp, Quest Files Objection to Correlogic's Motion to Reject OvaCheck Licensing Agreements

In its objection, Quest asserted that it retained rights to OvaCheck despite it being changed from a mass-spec-based assay to an immunoassay, and challenged Correlogic's claim that it was rejecting the agreements out of "sound business judgment."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.